Effective April 26, 2017, Bellerophon Therapeutics, Inc. (the “Company”) terminated the At Market Issuance Sales Agreement (the “Sales Agreement”) entered into on May 27, 2016 with FBR Capital Markets & Co. and MLV & Co. LLC (collectively, the “Distribution Agents”) to sell shares of its common stock, par value $0.01 per share (the “common stock”) having an aggregate offering price of up to $5,700,000 through the Distribution Agents. The Company has decided to terminate the Sales Agreement because it does not intend to utilize the Sales Agreement to raise additional capital.
All sales under the Sales Agreement were required to be made under the Company’s effective shelf registration statement on Form S-3 (File No. 333-211166) filed with the Securities and Exchange Commission and the related prospectus supplement dated May 27, 2016 and filed on May 27, 2016.
The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed as Exhibit 1.1 to a Current Report on Form 8-K filed by the Company on May 27, 2016 and is incorporated herein by reference.
About BELLEROPHON THERAPEUTICS, INC. (NASDAQ:BLPH) Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.
BELLEROPHON THERAPEUTICS, INC. (NASDAQ:BLPH) Recent Trading Information BELLEROPHON THERAPEUTICS, INC. (NASDAQ:BLPH) closed its last trading session down -0.03 at 1.45 with 900,992 shares trading hands.
Related
